May 10th 2024
A study presented at The Annual Conference on Vaccinology Research (ACVR) offers insights into the efficacy of seasonal influenza vaccines.
The federal agency said that due to administrative constraints, they will not complete the review of mRNA-1345 by the PDUFA date of May 12.
May 9th 2024
Stating low demand, the company is removing their ChAdOx1-S [recombinant] (Vaxzevria) vaccine from the market.
May 8th 2024
Insights from the Annual Conference on Vaccinology Research (ACVR) on vaccine registries and assessing the safety of maternal and fetal health.
The investigational vaccine, mRNA-1345, developed for seniors has its FDA PDUFA date in a few days.